Back to Search Start Over

Temporary autonomic modulation with botulinum toxin type A to reduce atrial fibrillation after cardiac surgery.

Authors :
Waldron, Nathan H.
Cooter, Mary
Haney, John C.
Schroder, Jacob N.
Gaca, Jeffrey G.
Lin, Shu S.
Sigurdsson, Martin I.
Fudim, Marat
Podgoreanu, Mihai V.
Stafford-Smith, Mark
Milano, Carmelo A.
Piccini, Jonathan P.
Mathew, Joseph P.
Source :
Heart Rhythm; Feb2019, Vol. 16 Issue 2, p178-184, 7p
Publication Year :
2019

Abstract

<bold>Background: </bold>Postoperative atrial fibrillation (POAF) frequently complicates cardiac surgery and is associated with worse outcomes. The cardiac autonomic nervous system is implicated in the pathogenesis of POAF.<bold>Objective: </bold>The purpose of this study was to determine the efficacy and safety of selective cardiac autonomic modulation in preventing POAF.<bold>Methods: </bold>In this randomized, double-blind, placebo-controlled trial, adults undergoing cardiac surgery were randomized 1:1 to intraoperative injection of 250 units onabotulinumtoxinA (botulinum toxin type A [BoNTA]) or placebo into epicardial fat pads. The study was powered to detect a 40% reduction in relative risk of POAF. Time to first episode of in-hospital POAF was the primary outcome, evaluated in patients receiving injection. Additionally, incidence of POAF, length of stay (LOS), and adverse events were examined.<bold>Results: </bold>The trial assigned 145 patients to injection, 15 of whom were dropped before treatment, leaving 130 patients for analysis. Overall, 36.5% (23/63) of BoNTA-treated patients developed POAF compared with 47.8% (32/67) of placebo-treated patients. The time-to-event analysis revealed a hazard ratio of 0.69 (95% confidence interval 0.41-1.19; P = .18) for the BoNTA vs placebo arm. There were no significant differences in postoperative hospital LOS (median [interquartile range] 6.0 [3.4] vs 6.2 [3.7] days; P = .51) or adverse events prolonging LOS (27/63 [42.9%] vs 30/67 [44.8%]; P = .83) in patients receiving BoNTA vs placebo.<bold>Conclusion: </bold>Epicardial injection of onabotulinumtoxinA was without discernible adverse effects, but we failed to detect a significant difference in risk of POAF. Future large-scale studies of epicardial onabotulinumtoxinA injection as a potential POAF prevention strategy should be designed to study smaller, but clinically meaningful, treatment effects. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
15475271
Volume :
16
Issue :
2
Database :
Supplemental Index
Journal :
Heart Rhythm
Publication Type :
Academic Journal
Accession number :
134227230
Full Text :
https://doi.org/10.1016/j.hrthm.2018.08.021